Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7982000 | 1.00 | CA2 (0.55) | CA2L3MBTL1LMNAMAPK1MTNR1A | |
| SCHEMBL1545420 | 1.00 | CA2 (0.55) | CA2L3MBTL1LMNAMAPK1MTNR1A | |
| SCHEMBL9446251 | 0.96 | CA2 (0.51) | CA2L3MBTL1LMNAMAPK1MTNR1A | |
| Piperoxan SCHEMBL9446249 | 0.87 | ADRA2A (0.70) | — | |
| SCHEMBL1545033 | 0.85 | CA2 (0.56) | CA2LMNAMTNR1AHTTSMN1; SMN2 | |
| SCHEMBL9451259 | 0.85 | CA2 (0.64) | CA2L3MBTL1LMNAMAPK1MTNR1A | |
| SCHEMBL14185726 | 0.82 | HTR6 (0.68) | CA2L3MBTL1LMNARECQLHTT | |
| SCHEMBL3153504 | 0.82 | HTR6 (0.68) | CA2L3MBTL1LMNARECQLHTT | |
| SCHEMBL9696426 | 0.82 | ALOX5 (0.58) | MTNR1ARECQLSMN1; SMN2 | |
| SCHEMBL3149144 | 0.82 | HTR6 (0.61) | CA2L3MBTL1LMNARECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ADRA2C, ADRA2A, HTR2C | CA2 872/4885L3MBTL1 2753/4885LMNA 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.